Program Book - Confex

ACR/ARHP Poster Session B
206
Khanna 6 , 1 University of Michigan, Ann Harbor, MI, 2 David
Geffen School of Medicine at UCLA, Los Angeles, CA, 3 UCLA,
Los Angeles, CA, 4 UCLA Medical School, Los Angeles, CA,
5
VA Medical Ctr, San Diego, CA, 6 University of Michigan, Ann
Arbor, MI
1026. Nonclinical Drug-Drug Interaction Profile of BCX4208, An
Oral, Once-Daily, Novel Nonmetabolized Enzyme Inhibitor
for Chronic Management of Gout. Paul G. Pearson 1 , Shanta
Bantia 2 and Leigh Harman 2 , 1 Pearson Pharma Partners,
Westlake Village, CA, 2 BioCryst Pharmaceuticals, Inc.,
Birmingham, AL
1027. Efficacy of Combined Treatment with Allopurinol and
Benzbromarone in Gout Patients with Chronic Renal
Impairment. Ji Seon Oh 1 , Seung Won Choi 1 , Bon San Koo 2 ,
Min Wook So 2 , Yong-Gil Kim 2 , Chang-Keun Lee 2 and Bin Yoo 2 ,
1
University of Ulsan College of Medicine, Ulsan University
Hospital, Ulsan, South Korea, 2 University of Ulsan College of
Medicine, Asan Medical Center, Seoul, South Korea
1028. Comparison of Pain Intensity, Incidence of New Flares,
Safety and Tolerability of Canakinumab Vs Triamcinolone
Acetonide in Gouty Arthritis Patients with Cardiovascular
Diseases or with Cardiovascular Risk Factors. N.
Schlesinger 1 , J. P. Brown 2 , T. Bardin 3 , T. Kiechle 4 , A. Shpilsky 5 ,
R. Alten 6 and A. So 7 , 1 UMDNJ-Robert Wood Johnson Medical
School, New Brunswick, NJ, 2 CHUQ (CHUL) Research Centre,
Laval University, Quebec City, QC, 3 Hôpital Lariboisière,
Paris, France, 4 Novartis Pharma AG, Basel, Switzerland,
5
Novartis Pharmaceutical Corporation, East Hanover, NJ,
6
Charité Teaching Hospital–Schlosspark-Klinik, Berlin,
Germany, 7 CHUV, Lausanne, Switzerland
1029. Efficacy of Canakinumab on Re-Treatment in Gouty
Arthritis Patients with Limited Treatment Options:
24-Week Results From β-RELIEVED and β-RELIEVED-II
Studies. R. Alten 1 , A. So 2 , A. Kivitz 3 , T. Bardin 4 , M. Bloch 5 , A.
Gimona 6 , A. Widmer 6 , G. Krammer 6 , N. Schlesinger 7 and H.
R. Schumacher 8 , 1 Charité Teaching Hospital–Schlosspark-
Klinik, Berlin, Germany, 2 CHUV, Lausanne, Switzerland,
3
Altoona Center for Clinical Research, Duncansville, PA,
4
Hôpital Lariboisière, Paris, France, 5 Holdsworth House
Medical Practice, Sydney, Australia, 6 Novartis Pharma AG,
Basel, Switzerland, 7 UMDNJ-Robert Wood Johnson Medical
School, New Brunswick, NJ, 8 University of Pennsylvania and
VA Medical Center, Philadelphia, PA
1030. Pharmacokinetics, Efficacy and SAFETY of Lesinurad,
A NOVEL URAT1 Inhibitor, In Individuals with Mild to
Moderate Renal IMPAIRMENT. David Hagerty, Brad Kerr,
Zangong Shen, Li-tain Yeh, Vijay Hingorani, Matt Cravets,
Jody Welp, Jeffrey N. Miner, Kimberly Manhard and Barry
Quart, Ardea Biosciences, Inc., San Diego, CA
1031. The Impact On Renal Function of Quantitative Serum Urate
Reduction In Gout Patients. Andrew Whelton 1 , Patricia A.
MacDonald 2 , Barbara Hunt 2 and Lhanoo Gunawardhana 2 ,
1
The Johns Hopkins University and Universal Clinical
Research Center, Inc., Baltimore, MD, 2 Takeda Global
Research & Development Center, Inc., Deerfield, IL
2011 Program Book
1032. Uncontrolled Serum Uric Acid Is Associated with An
Increased Risk of Developing Renal Disease In Veterans
with Gout. Eswar Krishnan 1 , Hari Sharma 2 , Bhavik J. Pandya 3 ,
Maryna Marynchenko 2 , Andrew Yu 2 , Eric Wu 2 , Jinan
Liu 4 and Lizheng Shi 4 , 1 Stanford University, Stanford, CA,
2
Analysis Group, Inc., Boston, MA, 3 Takeda Pharmaceuticals
International, Inc., Deerfield, IL, 4 Tulane University, New
Orleans, LA
1033. Clinical Characteristics of Difficult-to-Treat Gout Patients:
a Principal Components Analysis. Elizaveta Vaysbrot 1 ,
Yoojin Lee 1 , Sarah McLaughlin 1 , Neetu Agashivala 2 , Anthony
Yadao 3 , Timothy E. McAlindon 1 and William F. Harvey 1 ,
1
Tufts Medical Center, Boston, MA, 2 Novartis Pharmaceutical
Corporation, East Hanover, NJ, 3 Novartis Pharmaceuticals
Corporation, East Hanover, NJ
1034. Predictors of Outcomes in Gout with Comorbid Chronic
Kidney Disease. Ankoor Shah and John S. Sundy, Duke
University Medical Center, Durham, NC
1035. Patient Management/Treatment and Outcomes of Gout
Between Primary Care Physicians and Rheumatologists:
A Chart Review of 1,039 Patients with Gout In the
United States. Dinesh Khanna 1 , Anna Forsythe 2 and Puja
Khanna 1 , 1 University of Michigan, Ann Arbor, MI, 2 Savient
Pharmaceuticals, Inc., East Brunswick, NJ
1036. Adverse Reactions to Allopurinol Are Not Increased In
Patients Exposed to Doses Higher Than Recommended
for Creatinine Clearance: A Retrospective Study of A Large
Urban Multispecialty Group. Tawatchai Paisansinsup 1 and
John T. Schousboe 2 , 1 Park Nicollet Health Services, St. Louis
Park, MN, 2 Park Nicollet Health Services, Minneapolis, MN
1037. Oral Urate Lowering Therapies in Chronic Gout: A
Systematic Review and Meta-Analysis. Puja Khanna 1 ,
Manjit K. Singh 2 , Sangmee Bae 2 , John D. FitzGerald 3 ,
Shraddha Prakash 4 , Marian Kaldas 4 , Maneesh Gogia 4 ,
Paul Maranian 5 , Robert Terkeltaub 6 and Dinesh Khanna 1 ,
1
University of Michigan, Ann Arbor, MI, 2 David Geffen School
of Medicine at UCLA, Los Angeles, CA, 3 UCLA David Geffen
School of Medicine, Los Angeles, CA, 4 UCLA, Los Angeles,
CA, 5 University of California, Los Angeles, 6 VA Medical Ctr,
San Diego, CA
Miscellaneous Rheumatic and Inflammatory Diseases
1038. A Case Series of HLA B27 Patients with a Behçet’s Like
Syndrome in a UK Population. Nicola Ambrose 1 and Dorian
O. Haskard 2 , 1 Imperial College London, London, United
Kingdom, 2 Imperial College, London, United Kingdom
1039. Dual Effects of Testosterone in Behcet’s Disease:
Implications for a Role in Disease Pathogenesis. Sule
Yavuz 1 , Tugba Akdeniz 2 , Muge Bicakcigil 2 , Haner Direskeneli 1
and Gulderen Yanikkaya Demir 2 , 1 Marmara University,
Istanbul, Turkey, 2 Yeditepe University, Istanbul, Turkey
1040. Major Arterial Involvement in Behçet’s Disease: Results
From a Single Centre about 29 Cases. Z. Tazi Mezalek,
W. Ammouri, H. Harmouche, M. Maamar, M. Bourkia, M.
Adnaoui and M. Aouni, Ibn Sina Hospital, Rabat, Morocco